Targeting Cancer Cells with Smart, Internalizing Antibodies
This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present.
Original patent title: “Multispecific antigen-binding molecule with improved internalization characteristics”
This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present. Owned by Genmab AS with 55 claims and 1 forward citation, and it is expected to expire in 2042.
Coverage
What does this patent actually cover?
This patent describes a special molecule, like an antibody, that has two specific parts, called antigen-binding domains. The first part is designed to attach to a 'target molecule (T)' often found on cancer cells (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1). The second part attaches to an 'internalizing effector protein (E)' (Claim 1), which is a protein on the cell surface that helps pull things inside. The key feature is that this second part has a very specific binding strength, or 'dissociation constant (KD),' for the effector protein (E), set between 10^-9 and 10^-8 M (Claim 1). This precise binding strength helps the entire molecule get pulled into the cell more efficiently, especially when the target molecule (T) is also present (Claim 8, 10). For example, a HER2xCD63 bispecific antibody (Claim 36) could be designed to deliver a drug inside HER2-positive cancer cells.
The gap
What does this patent NOT cover?
- Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Multispecific antibodies where the second binding domain's affinity (KD) for the internalizing effector protein (E) is outside the specified 10^-9 to 10^-8 M range (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Molecules that internalize into cells without requiring the presence of the target molecule (T) for enhanced internalization (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 8).
- Molecules where the effector protein (E) is not a cell surface molecule that is internalized into the cell (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 7).
- Molecules where the target (T) is not associated with a tumor or cancer (AbstractabstractA short summary at the front of the patent describing the invention. Not legally binding.Read more →, ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 35).
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever part is precisely defining the optimal binding strength (dissociation constant) for the second antigen-binding domain to an internalizing effector protein. This specific affinity range (10^-9 to 10^-8 M) is crucial for ensuring the molecule not only binds to the cell but also gets efficiently pulled inside and transported to the lysosomal compartment, especially when the cancer target is present (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1, 10). This fine-tuning enhances targeted delivery.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Antibody-drug conjugates (ADCs) for cancer treatment
Bispecific antibodies designed to deliver drugs into tumor cells
HER2-targeting therapies that require cellular uptake
CD63-targeting therapies for enhanced internalization
Why it matters
The bigger picture
This technology aims to improve how therapeutic molecules, like drugs, are delivered into cancer cells. Many effective cancer treatments need to get inside the cell to work properly. By making the delivery process more efficient and specific to cancer cells, this approach could lead to more potent treatments with fewer side effects, potentially improving patient outcomes.
Filed
April 6, 2022
Market context
Who's building on this
Companies in this space
Genmab AS, the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is a prominent company focused on developing innovative antibody therapeutics, including multispecific antibodies for cancer. Other major pharmaceutical and biotechnology companies, such as Amgen, Roche, and Johnson & Johnson, are also actively developing multispecific antibodies and antibody-drug conjugates, often exploring advanced delivery mechanisms to improve efficacy and target specificity in cancer treatment.
Market impact
This patent's technology could significantly advance the field of targeted cancer therapies, particularly antibody-drug conjugates and other internalizing therapeutics. By enabling more efficient and specific delivery of therapeutic agents into cancer cells, it could lead to the development of new drugs with improved efficacy and reduced systemic toxicity. This innovation has the potential to expand treatment options for various cancers and improve patient outcomes by making therapies more precise.
Claim 1 — Plain English
What this patent covers
This patent describes a special molecule, like an antibody, that has two specific parts, called antigen-binding domains. The first part is designed to attach to a 'target molecule (T)' often found on cancer cells (Claim 1). The second part attaches to an 'internalizing effector protein (E)' (Claim 1), which is a protein on the cell surface that helps pull things inside. The key feature is that this second part has a very specific binding strength, or 'dissociation constant (KD),' for the effector protein (E), set between 10^-9 and 10^-8 M (Claim 1). This precise binding strength helps the entire molecule get pulled into the cell more efficiently, especially when the target molecule (T) is also present (Claim 8, 10). For example, a HER2xCD63 bispecific antibody (Claim 36) could be designed to deliver a drug inside HER2-positive cancer cells.
The clever bit
The clever part is precisely defining the optimal binding strength (dissociation constant) for the second antigen-binding domain to an internalizing effector protein. This specific affinity range (10^-9 to 10^-8 M) is crucial for ensuring the molecule not only binds to the cell but also gets efficiently pulled inside and transported to the lysosomal compartment, especially when the cancer target is present (Claim 1, 10). This fine-tuning enhances targeted delivery.
What it does not cover
- Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (Claim 1).
- Multispecific antibodies where the second binding domain's affinity (KD) for the internalizing effector protein (E) is outside the specified 10^-9 to 10^-8 M range (Claim 1).
- Molecules that internalize into cells without requiring the presence of the target molecule (T) for enhanced internalization (Claim 8).
- Molecules where the effector protein (E) is not a cell surface molecule that is internalized into the cell (Claim 7).
- Molecules where the target (T) is not associated with a tumor or cancer (Abstract, Claim 35).
Patent timeline
Application submitted to the patent office
Patent enters public domain
PatentBrief Score
Impact Score
Moderate
Citation count
6/40
Early citations
Claim breadth
20/20
Very broad protection
Recency
0/20
Older than 20 years
Assignee scale
20/20
Major company or institution
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$144K – $461K
Midpoint $288K · 15.4 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
55 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
MELIS, J., Vink, T., BREIJ, E., Parren, P., Goeij, B. D., NAPEL, H. T., & Satijn, D. Targeting Cancer Cells with Smart, Internalizing Antibodies (U.S. Patent No. 20,230,076,417). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20230076417/multispecific-antigen-binding-molecule-with-improved-internalization-characteris
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US20230076417"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 20210055304 · Hoffmann La Roche
How to Measure Unbound Drug Target in a Sample
US 10138293 · 2018 · Hoffmann La Roche Inc
How Roche Engineers Antibodies to Target Two Different Diseases Simultaneously
US 20210301031 · Mersana Therapeutics
Targeted Cancer Drugs Using Antibodies and Polymer Scaffolds
US 20210205465 · Apo T BV
Targeting Bad Cells with Toxic Antibodies for Cancer and Autoimmune Disease
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Targeting Cancer Cells with Smart, Internalizing Antibodies cover?
This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present.
Who owns patent US 20230076417?
This patent is owned by Genmab AS.
When does this patent expire?
This patent is expected to expire on April 6, 2042, when the invention enters the public domain.
What is patent US 20230076417 cited by?
This patent has been cited by 1 later patents that build on its ideas.
What problem does this patent solve?
This technology aims to improve how therapeutic molecules, like drugs, are delivered into cancer cells. Many effective cancer treatments need to get inside the cell to work properly. By making the delivery process more efficient and specific to cancer cells, this approach could lead to more potent treatments with fewer side effects, potentially improving patient outcomes.
What does this patent NOT cover?
Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (Claim 1).
Patent monitoring





